Longboard Pharmaceuticals (Longboard Pharmaceuticals) Interest Expense : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Longboard Pharmaceuticals Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Longboard Pharmaceuticals's interest expense for the three months ended in Mar. 2024 was $ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Longboard Pharmaceuticals's Operating Income for the three months ended in Mar. 2024 was $ -18.11 Mil. Longboard Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $ 0.00 Mil. GuruFocus does not calculate Longboard Pharmaceuticals's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Longboard Pharmaceuticals Interest Expense Historical Data

The historical data trend for Longboard Pharmaceuticals's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Longboard Pharmaceuticals Interest Expense Chart

Longboard Pharmaceuticals Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Interest Expense

Longboard Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Interest Expense	Get a 7-Day Free Trial												-	-	-	-	-

Longboard Pharmaceuticals Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Longboard Pharmaceuticals (NAS:LBPH) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Longboard Pharmaceuticals's Interest Expense for the three months ended in Mar. 2024 was $0.00 Mil. Its Operating Income for the three months ended in Mar. 2024 was $-18.11 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2024 was $3.67 Mil.

Longboard Pharmaceuticals's Interest Coverage for the quarter that ended in Mar. 2024 is calculated as

GuruFocus does not calculate Longboard Pharmaceuticals's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Longboard Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

Longboard Pharmaceuticals (Longboard Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Longboard Pharmaceuticals Inc (NAS:LBPH) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

4275 Executive Square, Suite 950, La Jolla, CA, USA, 92037

Website

https://www.longboardpharma.com

Longboard Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases. The company is working to improve a portfolio of centrally acting product candidates designed to be selective for specific G protein-coupled receptors (GPCRs). The company is evaluating LP352, an oral, centrally acting 5-hydroxytryptamine 2C (5-HT2C) receptor superagonist, with negligible observed impact on 5-HT2B and 5-HT2A receptor subtypes, in development for the potential treatment of seizures associated with a broad range of developmental and epileptic encephalopathies.

Executives

Randall Kaye	officer: CMO	11388 SORRENTO VALLEY ROAD, STE. 200, SAN DIEGO CA 92121
Jane Tiller	director	C/O LONGBOARD PHARMACEUTICALS, INC., 4275 EXECUTIVE DRIVE, SUITE 950, LA JOLLA CA 92037
Brandi Roberts	officer: Chief Financial Officer	12390 EL CAMINO REAL #150, SAN DIEGO CA 92130
Phillip M Schneider	director	GEN-PROBE INCORPORATED, 10210 GENETIC CENTER DRIVE, SAN DIEGO CA 92121
Vincent Aurentz	director	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Kevin Robert Lind	director, officer: President and CEO	C/O ARENA PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Paul J Sekhri	director	C/O VEEVA SYSTEMS INC., 4637 CHABOT DRIVE, SUITE 210, PLEASANTON CA 94588
Casey Lynch	director	C/O CORTEXYME, INC., 269 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Le Goff Corinne	director	200 TECHNOLOGY SQUARE, SUITE 300, CAMBRIDGE MA 02139
Arena Pharmaceuticals Inc	10 percent owner	6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121
Philip Perera	officer: Chief Medical Officer	C/O LONGBOARD PHARMACEUTICALS, INC., 6154 NANCY RIDGE DRIVE, SAN DIEGO CA 92121